1,7-dimethylxanthine has been researched along with Parkinson Disease in 2 studies
1,7-dimethylxanthine : A dimethylxanthine having the two methyl groups located at positions 1 and 7. It is a metabolite of caffeine and theobromine in animals.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Caffeine half-life was also estimated from salivary concentrations of caffeine at 2 and 5 h post dose." | 1.31 | Parkinson's disease and CYP1A2 activity. ( Forsyth, JT; Grünewald, RA; Lennard, MS; Rostami-Hodjegan, A; Sagar, HJ; Tucker, GT, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsumura, N | 1 |
| Aoyama, K | 1 |
| Forsyth, JT | 1 |
| Grünewald, RA | 1 |
| Rostami-Hodjegan, A | 1 |
| Lennard, MS | 1 |
| Sagar, HJ | 1 |
| Tucker, GT | 1 |
1 review available for 1,7-dimethylxanthine and Parkinson Disease
| Article | Year |
|---|---|
Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Brain; Caffeine; Cysteine; Excitatory Amino Ac | 2023 |
1 other study available for 1,7-dimethylxanthine and Parkinson Disease
| Article | Year |
|---|---|
Parkinson's disease and CYP1A2 activity.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Female; Humans; Male; Middle Aged | 2000 |